Lifewave Biomedical, Inc.

Lifewave Biomedical, Inc. specializes in innovative health technology, focusing on advanced non-invasive devices that enhance patient monitoring and management of heart failure through sophisticated medical radar technology. Founded in 2000 in Los Altos, US, Lifewave Biomedical, Inc. develops non-invasive biomarker solutions for heart failure.

The company has engaged in 2 deals, with the latest funding round occurring in June 2019, raising USD 620,000. The founders, Paul Tupin and Pranam Shetty, have built a company committed to improving healthcare outcomes, while the current CEO is David Schmidt. LifeWave Biomedical's primary offering is the CardioConnect™ system, a non-invasive device that accurately captures biomarkers for worsening heart failure using advanced medical radar technology. This system aids clinicians in optimizing Guideline Directed Medical Therapy (GDMT), enhancing patient engagement and workflows for managing heart failure, and is scalable for diverse healthcare settings focusing on value-based care frameworks.

LifeWave Biomedical operates under a SaaS business model, providing the CardioConnect™ system to healthcare providers through a subscription-based approach. This structure supports effective heart failure monitoring by healthcare systems and clinicians, likely bolstered by partnerships with organizations that integrate this solution into their workflows. The company is also actively raising a Series B financing round to further its growth and development efforts. Lifewave Biomedical plans to expand its product offerings, particularly focusing on new innovations for heart failure management.

The company is also looking to target new healthcare markets outside the U. S. by leveraging insights from recent funding, which was raised in June 2019 from DigitalDx Ventures. This funding will support efforts to enhance product development and facilitate entry into broader geographic regions.